SCHEMBL1094470

SCHEMBL1094470

O=S(=O)(c1ccccc1)N(Cl)c1ccncn1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PKM P14618 1/20 0.40
KMT2A Q03164 3/20 0.40
APOBEC3G Q9HC16 1/20 0.39
HSD17B10 Q99714 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
GRM4 Q14833 1/20 0.38
POLB P06746 1/20 0.37
MEN1 O00255 2/20 0.35
GAA P10253 1/20 0.35
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
LMNA P02545 1/20 0.34
HSP90AA1 P07900 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5138358 0.81 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2KMT2AAPOBEC3GHSD17B10
SCHEMBL28335411 0.81 GRM4 (0.45) ALDH1A1SMN1; SMN2KMT2AHSD17B10GRM4
SCHEMBL28093349 0.81 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2PKMKMT2AAPOBEC3G
SCHEMBL1094424 0.81 APOBEC3G (0.47) ALDH1A1SMN1; SMN2PKMKMT2AAPOBEC3G
SCHEMBL21296528 0.75 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2PKMKMT2AAPOBEC3G
SCHEMBL27655633 0.72 KMT2A (0.36) ALDH1A1SMN1; SMN2PKMKMT2AAPOBEC3G
SCHEMBL6398896 0.69 APOBEC3G (0.52) ALDH1A1PKMKMT2AAPOBEC3GHSD17B10
SCHEMBL27597440 0.69 KMT2A (0.44) ALDH1A1SMN1; SMN2PKMKMT2AAPOBEC3G
SCHEMBL767099 0.68
SCHEMBL27731694 0.68 HSP90AA1 (0.40) ALDH1A1SMN1; SMN2PKMKMT2AAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-20130338111-A1 Sulfonamide Derivatives ICAGEN, INC. (US) 2013-12-19 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 ALDH1A1 1369/4885SMN1; SMN2 86/4885PKM 367/4885
US-20130338111-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 ALDH1A1 1369/4885SMN1; SMN2 86/4885PKM 367/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 ALDH1A1 1369/4885SMN1; SMN2 86/4885PKM 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.